Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

D. J. McGrail, P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, M. Khasraw, A. B. Heimberger, N. T. Ueno, R. Ferrarotto, J. T. Chang, S. Y. Lin

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)1194-1197
Number of pages4
JournalAnnals of Oncology
Issue number9
StatePublished - Sep 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this